According to the management, this is an isolated incident and the company should be back on track in the ... tax rate of 21%, Vertex should report net income of $6.42 billion in 2030 using earlier ...

Biotech company Vertex ... margin of 42.7%, down 7 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. We track the ...

The PGIM Jennison Growth Fund returned - $10.0%, matching the Russell 1000 Growth Index, which also returned -10.0% in Q1 ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

On Friday, BMO Capital Markets confirmed its positive stance on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), maintaining both the Outperform rating and the $557.00 price target for the ...

On Wednesday, Wolfe Research issued a rating downgrade for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), shifting from "Outperform" to "Peer Perform." The adjustment comes as the stock ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after ...

Vertex's share price is still in positive territory year to date despite today's pullback. I think the biotech stock remains an excellent long-term pick because of the growth prospects for ...